Cagrilintide is a novel, long acting peptide designed to target multiple receptors involved in appetite regulation and energy balance. Unlike traditional weight loss medications that often target a single pathway, cagrilintide acts as Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Amylin Injectable Cagrilintide Demonstrates Weight Loss of 11.8% in Late Stage Trial: Novo Nordisk Update Patient Care Online NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity TradingView News Pharmacy Cagrilintide monotherapy led to ~11.8% weight loss vs 2.3% with placebo over 68 weeks in the phase 3 REDEFINE 1 trial for adults with obesity or overweight plus comorbidities. Read more